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Carotid Endarterectomy: A Survey of European Vascular Surgeons
Hamish M., Gohel M.S., Shepherd A., Howes N.J., Davies A.H. Eur J Vasc
Endovasc Surg 2009;38:402-7.
Objectives: The peri-operative use of antiplatelet, anticoagulant and
other drugs for patients undergoing carotid endarterectomy (CEA) is un-
clear and consensus is lacking. This study aimed to assess the current
peri-operative practice of European vascular surgeons with respect to anti-
platelet and other medications for patients undergoing CEA.
Design: Online questionnaire study.
Methods:Members of the Vascular Society of Great Britain & Ireland
and European Society for Vascular Surgery were invited to complete an
online survey in March 2008. Surgeons were asked about their preferences
for the peri-operative administration of antiplatelet, statin and other medi-
cations for patients undergoing carotid endarterectomy.
Results: Partial or complete responses were received from 399/650
(61.4%) surgeons with a collective annual throughput of11500 CEA proce-
dures. For symptomatic and asymptomatic patients, 20/392 (5%) and 47/392
(12%) of surgeons would stop aspirin before surgery and 170/392 (43%) and
217/392 (55%) of surgeonswould stopClopidogrel prior toCEA.Of surgeons
who would stop Clopidogrel, 84/170 (49%) and 124/217 (57%) would do so
7 days before surgery for symptomatic and asymptomatic patients respec-
tively. 12/393 (3%) surgeons would prescribe one 75 mg dose of Clopidogrel
on the evening before surgery. Intra-operative Dextran was used selectively by
40/395 (10%).Only 78/393 (20%)would delay surgery to commence a statin.
Intra-operatively, 348/394 (88%) used intravenous heparin, which was re-
versed routinely by 47/348 (13%) and selectively by 60/348 (17%).
Conclusions: There appears to be broad consensus between vascular
surgeons in the pharmacological management of patients undergoing carotid
endarterectomy, although some variations do exist. Further clinical studies may
help clarify the optimum management strategy in this patient group.
Endovascular Repair of Stanford Type B Aortic Dissection: Early and
Mid-term Outcomes of 121 Cases
Guangqi C., Xiaoxi L., Wei C., Songqi L., Chen Y., Zilun L., Shenming W.
Eur J Vasc Endovasc Surg 2009;38:422-6.
Objective: To analyse the early and mid-term outcomes of endovascu-
lar repair of Stanford type B aortic dissection (B-AD) and to compare the
outcomes between acute type B aortic dissection (AAD) and chronic type B
aortic dissection (CAD).
Methods: The cohort included 121 consecutive patients under-
going endovascular repair for AAD (group A, n  72) and CAD
(group B, n  49) between January 2001 and December 2006. Fol-
low-up with clinical examinations and computed tomography (CT) was
performed post-intervention at 1, 6 and 12 months, and then yearly
thereafter.
Results: In groups A and B, respectively, the procedure success rates were
88.9% and 77.6%; the rates of postoperative endoleak were 11.1% and 22.4%;
the 30-daymortality rates were 1.4% and 8.2%; and the 30-day stroke rates were
4.2% and2.0%.Nopostoperative spinal cord ischaemia (SCI)was observed.The
mean follow-up periods for groups A and B were 14.4 11.0 months and
22.1 20.8months, respectively. Latemortality was 1.5% in groupA and 4.8%
in group B. In group A, the rates of complete false lumen (FL) thrombosis at
1 month, 1 year and 2 years postoperatively were 32.3%, 51.4% and 53.8%,
respectively, and in group B, 26.2%, 44.8%, and 50.0%, respectively.
Conclusion: Endovascular repair is feasible for both AAD and CAD,
with favourable short- and mid-term outcomes.
The Prevalence of Polyvascular Disease in Patients Referred for Periph-
eral Arterial Disease
Vidakovic R., Schouten O., Kuiper R., Hoeks S.E., FluW.-J., van Kuijk J.P.,
Goei D., Verhagen H.J.M., Neskovic A.N., Poldermans D. Eur J Vasc
Endovasc Surg 2009;38:435-40.
Objective: To objectively assess the presence of polyvascular disease in
patients with peripheral arterial disease and its relation to inflammation and
clinical risk factors.
Methods: A total of 431 vascular surgery patients (mean age 68 years,
men 77%) with atherosclerotic disease were enrolled. The presence of
atherosclerosis was assessed using ultrasonography. Affected territories were
962defined as: (1) carotid, stenosis of common or internal carotid artery of
50%, (2) cardiac, left ventricular wall motion abnormalities, (3) abdominal
aorta, diameter 30 mm and (4) lower limb, ankle–brachial pressure index
0.9. Cardiovascular risk factors and high-sensitivity C-reactive protein
(hs-CRP) levels were noted in all.
Results: One vascular territory was affected in 29% of the patients,
whereas polyvascular disease was found in 71%: two affected territories in
45%, three in 23% and four in 3% of patients. Levels of hs-CRP increased
with the number of affected vascular territories (p  0.001). Multivariable
logistic regression analysis showed age 70 years, male gender, body mass
index (BMI) 25 kg m2, and hs-CRP to be independently associated with
polyvascular disease.
Conclusion: Polyvascular disease is a common condition in patients
who have undergone vascular surgery. The level of systemic inflammation,
reflected by hs-CRP levels, is moderately associated with the extent of
polyvascular disease.
Predictors of Walking Distance After Supervised Exercise Therapy in
Patients with Intermittent Claudication
Kruidenier L.M., Nicolaï S.P.A., Ten Bosch J.A., de Bie R.A., Prins M.H.,
Teijink J.A.W. Eur J Vasc Endovasc Surg 2009;38:449-55.
Objective: To identify predictor variables for results after supervised
exercise therapy (SET), and to develop a clinical prediction model that aims
to predict a target walking distance for individual patients.
Design: Retrospective analyses on prospectively collected data.
Materials: Patients with intermittent claudication who participated in
a SET programme.
Methods: SET was conducted according to the guidelines of the Royal
Dutch Society for Physiotherapy. The main outcome measurement was the
absolute claudication distance (ACD) after 6 months of SET. Linear regression
analyses were conducted to identify independent predictor variables for ACD.
Results: In this cohort, 437 patients were analysed. Independent predic-
tor variables for post-treatmentACDwere baselineACD(P 0.001), smoking
behaviour (P 0.012) and body-mass index (P 0.041). A better baseline
ACDwas associated with a longer post-treatment ACDwhereas current smok-
ing and a higher body-mass index were associated with a shorter post-treatment
ACD. The final regression equation included baseline ACD, age, body-mass
index, smoking and pulmonary disease, and was translated into several clinical
prediction models. However, only 24.8–33.6% of the patients had an ACD
within the calculated target range.
Conclusions: Predictive variables for post-treatment ACD after
SET are baseline ACD, age, body-mass index, pulmonary disease and
smoking behaviour. However, translating the regression equation into a
clinical prediction model did not lead to a valid model for use in clinical
practice.
Drug Therapy for Improving Walking Distance in Intermittent Clau-
dication: A Systematic Review and Meta-analysis of Robust Random-
ised Controlled Studies
Momsen A.H., Jensen M.B., Norager C.B., Madsen M.R., Vestersgaard-
Andersen T., Lindholt J.S. Eur J Vasc Endovasc Surg 2009;38:463-74.
Objectives: To evaluate the efficacy of pharmacological interventions
in improving walking capacity and health-related quality of life for people
with intermittent claudication.
Datasources: We searched Medline, EMBASE, Cochrane library and
relevant websites for studies published from the start of the databases to
February 2009. In addition, reference lists were manually searched.
Reviewmethods:Based upon a power calculation, only robust (n 56),
peer-reviewed, double-blinded, randomised and placebo-controlled trials were
included.
The main outcomes evaluated were maximal walking distance
(MWD) and pain-free walking distance on a treadmill. Random models
were used in the statistical analysis, and chi-square test were used to test
for heterogeneity.
Results: Among 220 trials, only 43 trials fulfilled the quality criteria.
Treatment periods, follow-up and treadmill protocols varied substantially.
Vasodilator agents and phosphodiesterase inhibitors show robust significant
results compared to placebo, but the improvements in MWD are modest.
The highest benefit was caused by lipid-lowering agents, which in mean
